Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

A new therapeutic approach could help tackle radiation resistance in childhood brain tumors

2.

A large study found that monolayers were superior in detecting cancer.

3.

Novel Treatment Shows Promise for Oral Mucositis Caused by Radiation.

4.

Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars

5.

A study has developed molecular markers that predict meningioma recurrence.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot